Drug & intervention
topotecan
RxCUI 57308
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Topotecan
Topotecan, sold under the brand name Hycamtin among others, is a chemotherapeutic agent medication that is a topoisomerase inhibitor. It is a synthetic, water-soluble analog of the natural chemical compound camptothecin. It is used in the form of its hydrochloride salt to treat ovarian cancer, lung cancer and other cancer types. After GlaxoSmithKline received final FDA approval for topotecan on 15 October 2007, it became the first topoisomerase I inhibitor for oral use.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownA Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerNCT07365241 · 2026-07-02
RECRUITINGStudy Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung CancerNCT07189455 · 2025-12-12
RECRUITINGA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]NCT07099898 · 2025-08-11
RECRUITINGA Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06954246 · 2025-06-04
RECRUITINGStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834 · 2025-04-04
RECRUITINGA Study of PHST001 in Advanced Solid TumorsNCT06840886 · 2025-03-31
RECRUITINGLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCNCT06496048 · 2024-09-14
RECRUITINGARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerNCT06498479 · 2024-07-04
RECRUITINGA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210 · 2024-05-21
RECRUITINGStudy of LY01610 in Patients With Recurrent Small Cell Lung CancerNCT06128837 · 2024-03-03
RECRUITINGA Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)NCT05652686 · 2023-09-05
RECRUITINGDose Attenuated Chemotherapy in Compromised Patients With Lung CancerNCT05800587 · 2023-02-22
RECRUITINGOrganoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung CancerNCT07106528 · 2025-08-01
NOT_YET_RECRUITINGPM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerNCT06616532 · 2024-11-13
ACTIVE_NOT_RECRUITINGJK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung CancerNCT06581380 · 2024-09-16
NOT_YET_RECRUITINGA Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)NCT06500026 · 2024-08-07
ACTIVE_NOT_RECRUITINGSafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With ChemotherapyNCT06449209 · 2024-08-05
ACTIVE_NOT_RECRUITINGDAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent ChemotherapyNCT05990738 · 2024-02-14
ACTIVE_NOT_RECRUITINGTrilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving TopotecanNCT05874401 · 2023-10-13
ACTIVE_NOT_RECRUITINGStudy Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerNCT05740566 · 2023-05-31
ACTIVE_NOT_RECRUITINGClinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)NCT05153239 · 2022-07-22
COMPLETEDBerzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)NCT04768296 · 2021-03-29
COMPLETEDNab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung CancerNCT04213937 · 2020-01-31
UNKNOWNStudy of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung CancerNCT04073550 · 2019-10-31
UNKNOWNA Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)NCT04022876 · 2019-09-03
TERMINATEDM7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung CancersNCT03554473 · 2018-09-11
COMPLETEDClinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related SarcomasNCT03600649 · 2018-06-04
UNKNOWNStudy of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung CancerNCT03088813 · 2018-04-25
COMPLETEDDinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerNCT03098030 · 2017-06-01
COMPLETEDPembrolizumab vs Topotecan in Patients With Small Cell Lung CancerNCT02963090 · 2017-05-20
TERMINATEDStudy Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)NCT03061812 · 2017-04-11
COMPLETEDImmunotherapy as Second-line in Patient With Small Cell Lung CancerNCT03059667 · 2017-03-13
COMPLETEDTopotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung CancerNCT02980809 · 2017-03-01
UNKNOWNStudy in Patients With SCLC of Veliparib in Combination With TopotecanNCT03227016 · 2016-10-01
UNKNOWNClinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung CancerNCT02566993 · 2016-08-30
COMPLETEDLCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesNCT02649673 · 2016-03-23
TERMINATEDTrilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan ChemotherapyNCT02514447 · 2015-10-05
COMPLETEDEffectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerNCT02481830 · 2015-09-14
COMPLETEDTrial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersNCT02487095 · 2015-07-30
COMPLETEDPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesNCT02419495 · 2015-06-26
TERMINATEDConditions being studied
Small Cell Lung Cancer23Lung Cancer10Lung Cancer, Small Cell6Small-cell Lung Cancer6Carcinoma, Small Cell3Ovarian Cancer3Relapsed Small Cell Lung Cancer3Endometrial Cancer2Extensive Stage Small Cell Lung Cancer2Extensive-stage Small-cell Lung Cancer2Non Small Cell Lung Cancer2Primary Peritoneal Carcinoma2Small Cell Lung Cancer (SCLC)2Small Cell Lung Cancer Extensive Stage2Advanced Malignant Solid Neoplasm1Advanced Solid Tumors1Angiomatoid Fibrous Histiocytoma1Breast Cancer1Carcinoma, Neuroendocrine1Carcinoma, Non-Small -Cell Lung1
Research locations
Leading sponsors
GlaxoSmithKline9SCRI Development Innovations, LLC7AbbVie2Luye Pharma Group Ltd.2National Cancer Institute (NCI)2PharmaMar2Aileron Therapeutics, Inc.1Alliance Foundation Trials, LLC.1Amgen1Ascenta Therapeutics1BioNTech SE1Biotheus Inc.1Boehringer Ingelheim1Bristol-Myers Squibb1Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.